Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

about

Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

Item

http://www.wikidata.org/entity/Q38956434

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Efficacy and Safety of FOLFIRI ...... Colorectal or Gastric Cancer.

@en

type

Item

label

Efficacy and Safety of FOLFIRI ...... Colorectal or Gastric Cancer.

@en

prefLabel

Efficacy and Safety of FOLFIRI ...... Colorectal or Gastric Cancer.

@en

P1476

Efficacy and Safety of FOLFIRI ...... Colorectal or Gastric Cancer.

@en

P2093

Byung-Ho Nam

http://www.w3.org/2001/XMLSchema#string

Dae Young Zang

http://www.w3.org/2001/XMLSchema#string

Dong Bok Shin

http://www.w3.org/2001/XMLSchema#string

Eun-Kee Song

http://www.w3.org/2001/XMLSchema#string

Ho-Suk Oh

http://www.w3.org/2001/XMLSchema#string

Hye Jin Kang

http://www.w3.org/2001/XMLSchema#string

Hye Sook Han

http://www.w3.org/2001/XMLSchema#string

Ik-Joo Chung

http://www.w3.org/2001/XMLSchema#string

Jee Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jeong-Eun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.

Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer.

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

P304

293-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2016-0166

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28209749

http://www.w3.org/2001/XMLSchema#string

P932

5344645

http://www.w3.org/2001/XMLSchema#string